ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ScinoPharm Teams Up For Chinese Cancer Market

by Jean-François Tremblay
May 20, 2013 | APPEARED IN VOLUME 91, ISSUE 20

Two Taiwanese firms, ScinoPharm and Coland, will work together to supply generic cancer drugs to China. ScinoPharm is a Tainan-based custom producer of active pharmaceutical ingredients and mostly supplies clients in the U.S. and Europe. Formed 10 years ago, Coland’s core business is to commission and distribute generic drugs for sale to the Chinese market. They will collaborate with a third company, not yet selected, to develop, formulate, and register the drugs in China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment